
Morgan Stanley Downgrades Moderna (MRNA) Stock Before Its Meeting with FDA Today
Morgan Stanley has asked investors not to make any fresh entry in MRNA stock citing potential downside in the short-term. Moderna is having a meeting with the FDA officials later today for approval of its COVID-19 vaccine candidate.